Olinvacimab
Based on 1 Customer Validation
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: ≥95.0%
- No. CAS: 2095504-49-5
- Peso molecular:148.16 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas VEGFR
More
Actividad biológica
IgG1-Vlambda-Ckappa
Human
VEGFR2/KDR/CD309
Olinvacimab (0-1000 nM) inhibits binding of VEGF to its receptor KDR with a Kd value of 0.23 nM[1]. Olinvacimab inhibits VEGF-165, VEGF-C and VEGF-D binding to VEGFR-2 with IC50 values of 8.7, 6.3 and 7.0 nM, respectively[1]. Olinvacimab (0.5-30 μg/mL; 30 min) inhibits the phosphorylation of VEGFR-2/KDR and ERK[1]. Olinvacimab (1, 15 and 20 mg/mL; 30 min) inhibits VEGF-induced proliferation of HUVEC[1]. Olinvacimab (20 mg/mL; 30 min) inhibits VEGF-stimulated HUVEC migration[1]. Olinvacimab (5, 10 and 20 μg; 20 h) dose-dependently inhibits tube formation and disorders tubular structures[1]. Olinvacimab (1 and 20 μg; 6 d) inhibits hVEGF165-induced rat aortic ring vessel sprouting[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cell (HUVEC) line
-
Concentration:0.5, 1, 5, 10, 20 and 30 μg/mL
-
Incubation Time:30 min
-
Result:Inhibited VEGF-induced phosphorylation of VEGFR-2 and ERK (downstream signaling molecule) in HUVECs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Matrigel-implanted nude mice model[1]
-
Dosage:100 ng
-
Administration:Subcutaneous injection; 100 ng, once
-
Result:Inhibited the neovascularization induced by hVEGF165.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-Vlambda-Ckappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 HUVEC cells with Olinvacimab (HY-P99768, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
No. CAS 2095504-49-5
-
Appearance Liquid
-
Peso molecular 148.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Olinvacimab]
-
Synonyms
TTAC-0001; Tanibirumab
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Olinvacimab Related Classifications
HY-P99768 Related Classifications
Powered by Bioz